Skip to main
PHR

Phreesia Inc (PHR) Stock Forecast & Price Target

Phreesia Inc (PHR) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Phreesia is experiencing short-term pressure in its revenue growth due to the current macroeconomic environment in the healthcare market, but the company remains confident in its strong reputation and ability to adapt to industry standards and evolving technology. Additionally, the recent expansion of its securitization facility with PNC Bank will give Phreesia more flexibility to expand its services, including its AccessOne platform, which the company is still in the early stages of scaling. While there are potential near-term challenges, Phreesia's solid financials and strategic acquisitions make it a strong player in the healthcare technology market in the long-term.

Bears say

Phreesia is facing several challenges in the healthcare market including a decline in revenue and pressure on margins, causing the company to shift from a "Rule of 40" to a "Rule of 30s" business model. Additionally, the company's aggressive pricing strategies may not be sustainable in the long-term, and there are concerns about potential competition in the market. These factors, along with potential downside risks such as economic downturn and slowdown of organic growth, contribute to a negative outlook on Phreesia's stock.

Phreesia Inc (PHR) has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Phreesia Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Phreesia Inc (PHR) Forecast

Analysts have given Phreesia Inc (PHR) a Buy based on their latest research and market trends.

According to 15 analysts, Phreesia Inc (PHR) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Phreesia Inc (PHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.